IAG to Attend Biotech Week of Meetings in San Francisco, USA, 12-15 January 2020

News

IAG to Attend Biotech Week of Meetings in San Francisco, USA, 12-15 January 2020

IAGs’ bio-partnering and management team will be attending biotech week in San Francisco.  IAG’s CEO, Dr. Olga Kubassova will attend JP Morgan meeting and Bio-Partnering Director and Head of Therapeutic Innovation, Dr. Diana Roettger will be attending Biotech Showcase and satellite events in San Francisco, USA, from January 12-15, 2020.

‘We see an increasing demand for an expert driven targeted development strategy, that often brings together smart use of technology, advanced imaging and AI. This de-risks biotech investors risks and increases changes of success, especially in early efficacy studies,’ said Dr. Diana Roettger of IAG.

Bio-Partnering is an independent investment division of IAG. We are building a diversified investment portfolio of innovative life science companies at various stages of clinical development. By bringing strategic collaborators and smart investments, we support their drug development efforts through clinical trials to market entry.
Our biotech portfolio companies take advantage of a range of innovative R&D solutions, risk-sharing financing and partnership models, early visibility of study performance through DYNAMIKA platform and tailored strategy for potential pharmaceutical partnerships.
We directly invest or provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immune-oncology, oncology, inflammation, rheumatology, musculoskeletal, immunology markets.

‘Our Bio-Partnering team has signed 6 successful partnerships with blue-chip pharma companies, public and private biotechnology players in 2019. We are excited to start 2020 and look forward to attending biotech week in San Francisco’, added Dr. Olga Kubassova, CEO of IAG.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News

Join IAG’s Expert Team at EULAR 2023: Novel ideas for drug development

Drug development ideas in osteoarthritis, psoriatic arthritis and scleroderma.

Dr Kubassova joins Fast Growth Icons & Female Founders Reception

The Invitation-only network for founders &CEOs of the most successful scaleups.

Dr Kubassova joins Rothschild’s Healthcare Dinner the National Gallery

Dr Kubassova is a leading innovator and passionate investor in healthcare.

IAG and AltruBio Partner to Deploy IAG’s AI methods in GI

Presenting new data from Ulcerative Colitis trial at DDW 2023.

Events